

INDUSTRY INSIGHT

CLINICAL TRIALS INDIA

November 2005

Cygnus

Business Consulting & Research

Knowledge Partner For Profitable Growth

4th & 5th Floors, Astral Heights, Road No. 1, Banjara Hills, Hyderabad-500034, India

Tel: +91-40-23430203-07, Fax: +91-40-23430201, E-mail: info@cygnusindia.com

Website: www.cygnusindia.com

Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by **Cygnus Business Consulting & Research** (Cygnus). While reasonable care has been taken in its preparation, Cygnus makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. The information contained herein may be changed without notice. All information should be considered solely as statements of opinion and Cygnus will not be liable for any loss incurred by users from any use of the publication or contents

SYNOPSIS

INDUSTRY INSIGHT: CLINICAL TRIALS IN INDIA

CLINICAL TRIALS – INDIA

India is fast-emerging as an attractive destination for clinical trials. Today, the market value of clinical research outsourced to India is estimated at US\$100 million. A clinical trial is a costly as well as time-consuming process. The cost of conducting clinical trials for a specific drug ranges between US\$350 and US\$500 million. Now about 20 organizations in India specialize in clinical trials. These companies have the skills to comply with standards such as ICH-GCP guidelines.

Currently, 20 to 30 per cent of the clinical development activity is outsourced to Clinical Research Organizations (CROs) in developing countries such as India due to lower costs. The cost of conducting clinical trials in India ranges between 20 and 60 per cent of the cost in western countries. According to industry sources, a volunteer in a developing country is paid between US\$70 and US\$350, based on the nature of the study, for participating in three studies a year. By contrast, volunteers in western countries are paid relatively higher amounts.

Not surprisingly, research-based global drug companies are keen to outsource clinical trials to developing countries such as India. Today, about 80 government and private hospitals in India are engaged in global and local clinical trials. Multinationals drug companies are also entering India, drawn by the vast pool of scientific talent. The multinationals in the CRO segment include ICON Clinical Research, Omnicare Clinical Research, Pharmanet global, Pharm-Olam, ClinTec International and Quintiles Spectral. The Indian clinical market is likely to be worth US\$1.5-2 billion by 2010, provided the number of patients in Indian trial sites constitutes 20 per cent of patients in global clinical trials.

SCOPE OF THE REPORT

This report provides an in-depth understanding of clinical trials in India. While front-end sections such as Executive Summary and Highlights provide the essence of the report in a few pages, the remaining part of the report provides an exhaustive analysis of clinical trials in India.

The middle of the report focuses on market scenario and major players. It also comprises an in-depth analysis of the growth prospects of the industry. The report also covers issues such as technology, growth factors and critical success factors. The regulatory framework, under which the trials are conducted, is discussed briefly. The report also comprises a separate section on the issues and challenges confronting CRO's.

The end section of the report contains an outlook for clinical trials in India besides utilities such as glossary. In the outlook section, the report builds upon the information and analysis of the previous chapters to forecast future trends.

BENEFITS

Life Sciences companies and the companies, which provide services to life sciences companies, will find this report useful. This report provides a deep understanding of clinical trials in India. Clinical research Organizations (CROs) in India, which are already engaged in clinical trials, will find this report useful in putting their performance in perspective and fine-tuning their strategies as well. For companies planning to enter the clinical trials segment, this report will provide an overview of the current situation and issues that may crop up in the latter part of the trials.

Bioservices, which is the fast-growing segment in the industry, is also covered in the report. This report will be useful to companies engaged in biotech services. It will also help Doctors (Investigators), the sponsors of trials and drug companies. Students, who plan to get into clinical trials, will certainly benefit from this report. The drug companies may use this report as a ready-reckoner and a source of latest information.

CONTENTS

| | |
|---|-----------|
| EXECUTIVE SUMMARY | 7 |
| HIGHLIGHTS..... | 10 |
| 1. INTRODUCTION | 12 |
| 1.1 A Brief History..... | 12 |
| 1.2 Effectiveness and Safety | 17 |
| 1.3 Clinical Trials: Benefits galore | 18 |
| 1.3.1 Research and Innovation | 18 |
| 1.3.2 Investigational New Drug application (IND) | 19 |
| 1.4 Global Scenario | 20 |
| 1.5 Indian Scenario..... | 21 |
| 1.5.1 Rising tide of research and clinical trials | 23 |
| 1.5.2 India as a destination for CROs | 24 |
| 1.5.3 Potential of CRO industry | 25 |
| 1.5.5 Major Diseases | 26 |
| 1.5.6 Infrastructure facilities | 27 |
| 1.5.7 Competitors in the sector | 28 |
| 1.5.8 Laboratory Trials (Pre-clinical trials)..... | 28 |
| 1.5.9 Recent Trends | 29 |
| 1.5.10 Trends in Drug Development | 31 |
| 1.5.11 Regulatory Developments..... | 32 |
| 1.5.12 Ethical Review Boards | 33 |
| 2. MARKET SCENARIO | 35 |
| 2.1 Global Scenario | 35 |
| 2.1.1 Worldwide New Drug Launches..... | 35 |
| 2.1.2 Biotech/Biological Launches | 36 |
| 2.1.3 Laboratory-developed Tests | 36 |
| 2.1.4 Inspections..... | 36 |
| 2.1.5 Education and Training Requirements..... | 37 |
| 2.1.6 Quality Control | 37 |
| 2.2 Market data and R&D productivity | 37 |
| 2.3 Drug withdrawals/Clinical Trial failures | 38 |
| 2.4 Research on Drug Price Controls | 38 |
| 2.4.1 Loss of Future Drug Therapy | 39 |
| 2.4.2 Slowdown in Drug Availability | 39 |
| 2.5 Indian Scenario..... | 40 |
| 2.5.1 Indian Companies..... | 41 |

| | |
|---|-----------|
| 2.5.2 Multinational Companies..... | 41 |
| 2.5.3 Outsourcing Clinical trials | 42 |
| 2.5.4 Clinical Trial components..... | 44 |
| 2.5.5 Support services in clinical trials | 46 |
| 2.5.6 Market related factors | 48 |
| 3. MAJOR PLAYERS..... | 53 |
| 3.1 Market Size..... | 54 |
| 3.2 Tata Memorial Centre | 54 |
| 3.3 Major Players..... | 55 |
| Listed Companies | 55 |
| 3.3.1 Clinigene..... | 55 |
| 3.3.2 Dr Reddy's Laboratories Limited..... | 58 |
| 3.3.3 GlaxoSmithKline | 61 |
| 3.3.4 Lupin Limited | 64 |
| 3.3.5 Novartis..... | 66 |
| 3.3.6 Pfizer Limited | 68 |
| 3.3.7 Ranbaxy Laboratories Limited | 72 |
| 3.3.8 Torrent Pharmaceuticals Limited | 75 |
| 3.3.9 Vimta Labs Limited | 78 |
| 3.3.10 Zydus Cadila..... | 81 |
| Unlisted Companies..... | 83 |
| 3.3.11 Asian Clinical Trials Limited | 83 |
| 3.3.12 Clininvent Research Pvt. Ltd.,..... | 85 |
| 3.3.13 ClinTec International..... | 88 |
| 3.3.14 Eli Lilly and Company (India) Pvt. Ltd | 90 |
| 3.3.15 iGATE Clinical Research International..... | 92 |
| 3.3.16 Intas Pharmaceuticals..... | 94 |
| 3.3.17 Johnson & Johnson, India..... | 96 |
| 3.3.18 Lambda Therapeutic Research Ltd..... | 99 |
| 3.3.19 Lotus Labs Pvt. Ltd. | 101 |
| 3.3.20 Matrix Laboratories Ltd. | 103 |
| 3.3.21 Merck Limited | 105 |
| 3.3.22 Novo Nordisk India Private Ltd. | 107 |
| 3.3.23 Pharmanet | 109 |
| 3.3.24 Quintiles Technologies (India) Private Limited | 112 |
| 3.3.25 Reliance Clinical Research Services | 114 |
| 3.3.26 Roche India Ltd.,..... | 116 |
| 3.3.27 Sanofi-Aventis (Aventis Pharma Limited)..... | 118 |
| 3.3.28 Siro Clinpharm Pvt Ltd. | 120 |
| 3.3.29 SRL Ranbaxy..... | 122 |
| 3.3.30 Synchron Research Pvt. Ltd. | 125 |
| 3.4 Support services | 127 |

| | |
|--|------------|
| 3.4.1 Companies entering into support services | 127 |
| 3.4.2 IT-pharma ventures..... | 128 |
| 3.4.3 Other IT/ITES companies' bio-initiatives | 128 |
| 3.4.4 Future of support services | 129 |
| 4. TECHNOLOGY | 131 |
| 4.1 Drug Development..... | 131 |
| 4.2 Biochemistry of the Drugs..... | 132 |
| 4.3 Drug Design..... | 133 |
| 4.3.1 The challenges in drug design | 134 |
| 4.3.2 Computers in drug design..... | 135 |
| 4.3.3 RACHEL Software Package | 137 |
| 4.4 Animal Studies..... | 139 |
| 4.5 Field Studies..... | 139 |
| 4.6 Bioavailability (BA) / Bioequivalence (BE) studies | 142 |
| 4.6.1 Types of studies..... | 142 |
| 4.6.2 Facilities for Conducting Bioavailability and/Or Bioequivalence Studies..... | 145 |
| 4.7 Recent Trends in Technology..... | 148 |
| 5. GROWTH DRIVERS | 150 |
| 5.1 Claims of Superiority | 150 |
| 5.2 Availability of Patients..... | 151 |
| 5.3 Infrastructure Facilities | 152 |
| 5.3.1 Availability of Animal Houses..... | 152 |
| 5.3.2 Hospitals..... | 154 |
| 5.3.3 Facilities for Clinical Trials | 154 |
| 5.3.4 Biotechnology Laboratories | 156 |
| 5.4 Drug development and price control..... | 157 |
| 5.4 Reduction in R&D expenses..... | 158 |
| 5.5 Decrease in Time-to-Market Clinical Trials..... | 159 |
| 5.6 Regulations and Support from Local Bodies..... | 160 |
| 5.7 FDA Approval | 160 |
| 5.7.1 Clinical Trials and FDA | 161 |
| 5.7.2 Clinical Trial Process | 162 |
| 6. CRITICAL SUCCESS FACTORS | 165 |
| 6.1 Infrastructure | 165 |
| 6.2 Research Design | 166 |

| | |
|--|------------|
| 6.3 Speed and Quality of trials..... | 166 |
| 6.4 Professionally Trained Manpower | 168 |
| 6.5 Hospitals..... | 168 |
| 6.6 Role of radiology..... | 168 |
| 6.7 Product Pricing and Market Analysis | 170 |
| 6.8 Drug Imports..... | 171 |
| 6.9 Multiple tasks in approvals..... | 172 |
| 6.10 Government Procedures/Sanctions | 173 |
| 7. REGULATORY ISSUES..... | 174 |
| 7.1 Government Regulations | 174 |
| 7.1.1 FDA..... | 174 |
| 7.2 Patent Regime..... | 175 |
| 7.2.1 Importance of Intellectual Property Rights (IPR)..... | 176 |
| 7.3 Customs Duty | 177 |
| 7.4 GATT / TRIPS / WTO | 178 |
| 7.5 Clinical Evaluation of Herbal Remedies and Medicinal Plants..... | 178 |
| 7.5.1 Categories of Herbal Products | 179 |
| 7.5.2 Guidelines | 180 |
| 7.6 Unsafe Drugs..... | 181 |
| 7.7 Industry's Growing Influence over Research | 181 |
| 7.8 Academia & Industry – Eroding boundaries..... | 182 |
| 7.9 Regulatory System in India..... | 183 |
| 7.9.1 Exemption of Customs Duty | 185 |
| 7.9.2 Tax benefit | 185 |
| 7.9.3 Role of IACUC | 186 |
| 7.10 Regulation of Ethical Issues | 187 |
| 7.10.1 Ethics of Patenting DNA | 187 |
| 7.10.2 Mental Disorders and Genetics..... | 188 |
| 7.10.3 Animal-to-Human Transplants: Ethics of Xenotransplantation..... | 189 |
| 7.10.4 Human Tissue: Ethical and Legal Issues | 189 |
| 7.10.5 Clinical Trials without Ethical Review..... | 190 |
| 8. ISSUES AND CHALLENGES | 192 |
| 8.1 Training for Clinical Trials | 192 |
| 8.1.1 Training Opportunities..... | 193 |
| 8.2 Clinical Trials - Design & Management..... | 194 |

| | |
|--|------------|
| 8.2.1 Good Clinical Practices (GCP)..... | 194 |
| 8.3 Quality of Clinical Trial Data | 196 |
| 8.4 Finding people for trials is always difficult..... | 196 |
| 8.5 Segmenting Physicians | 197 |
| 8.6 Protecting Research and Research Participants | 198 |
| 8.7 Ethical Problems..... | 198 |
| 8.7.1 The role of ethics in clinical trials | 199 |
| 8.7.2 Three major ethical problems | 199 |
| 8.7.3 Scientific and Ethical Standards | 200 |
| 8.8 Illegal Clinical Trials | 200 |
| 8.9 Studies in the Developing World..... | 201 |
| 8.10 Data Protection..... | 202 |
| 8.11 Assessing Risks and Benefits..... | 202 |
| 8.12 Host Country’s Capacity to Review and Conduct Clinical Trials | 203 |
| 8.13 Additional FDA guidelines for conducting trails..... | 203 |
| 8.13.1 Clinical Trials Conducted Outside United States | 204 |
| 8.13.2 Clinical Trial Registration | 205 |
| 8.13.3 Computerized Clinical Research Systems | 208 |
| 8.14 Clinical trials in India - Challenges..... | 209 |
| 8.14.1 Addressing the challenges | 210 |
| 9. FUTURE OUTLOOK | 212 |
| BIBLIOGRAPHY | 214 |
| GLOSSARY..... | 215 |
| ANNEXURE 1..... | 221 |
| Good Clinical Practices (GCP)..... | 221 |
| ANNEXURE 2..... | 234 |
| A Comparison of FDA vs. ICH Regulations | 234 |
| ANNEXURE 3..... | 237 |
| Good Manufacturing Practices..... | 237 |
| ANNEXURE 4..... | 253 |
| A New Chapter Opens..... | 253 |